Connect with us

Cannabis

Chlorella Market to Grasp Outstanding Growth of USD 448.67 Million by 2029, Size, Share, Trends, Growth Opportunities, Key Drivers and Competitive Outlook

Published

on

<!– Name:DistributionId Value:8805433 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:5377 –> <!– Name:CustomerId Value:1201301 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:8211e622-c4bd-4f52-8706-65325320bdf6 –>

SYDNEY, April 11, 2023 (GLOBE NEWSWIRE) — Data Bridge Market research has recently published comprehensive business research on “Chlorella Market” which includes historic data, present market trends, future product environment, marketing strategies, innovation, emerging trends or opportunities, and the technical progress in the related industry. A wide-ranging Chlorella report proves to be the supreme and excellent market report as it is generated with the following critical factors. These consist of primary research, benchmarking studies, secondary research, company profiles, competitive intelligence, & reporting, syndicated research, data collection, data processing and analysis, survey design, and survey programming. The report performs market study and analysis to provide market data by considering new product development from beginning to launch. The worldwide Chlorella marketing report also provides evaluations based on the market type, organization size, availability on-premises, end-users organization type, and availability in areas such as North America, South America, Europe, Asia-Pacific, and Middle East & Africa.

Besides, the Chlorella market research report offers CAGR value fluctuations during the forecast period for the market. The report puts light on probable and key opportunities in the new geographical market. The report takes into consideration all the opportunities, challenges, drivers, market structures, and competitive landscape for the clients. With this market report, it has been assured that unconditional knowledge and insights about the new regulatory environment which suits to their organization are provided. Likewise, the trends in consumer and supply chain dynamics are also acknowledged, and then accordingly strategies for marketing, promotion, and sales are interpreted for extreme success.

Data Bridge Market Research analyses that the chlorella market was valued at USD 275.21 million in 2021 and is expected to reach the value of USD 448.67 million by 2029, at a CAGR of 6.30% during the forecast period. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, geographically represented company-wise production and capacity, network layouts of distributors and partners, detailed and updated price trend analysis and deficit analysis of supply chain and demand.

Get Access to a Sample PDF of the Chlorella Market @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-chlorella-market

Chlorella is high in protein and has many nutritional and health benefits. Chlorella is a spherical chlorophyll division which belongs to the chlorophyta family. It consists of different active ingredients such as dietary amino acids, beta-carotene, RNA/DNA, fatty vitamins and over 20 essential vitamins and minerals. It is also used for the treatment of constipation, fibromyalgia, high cholesterol and blood sugar levels and cancer.

The increasing the vegan population across the globe, changing lifestyle of the people, rising consumption of the chlorella supplements by the health conscious people, increased demands due to its various health benefits are the main factors that are driving the market growth over the forecasted period. Moreover, the rising initiatives by the government to promote organic farming along with the rising usage of chlorella in personal care products such as skin care, haircare and others will generate lucrative growth opportunities for the chlorella market over the forecasted period.

The Global Market Is Analyzed in Depth in the Latest Study. Taking into account the current level of competition and its projected evolution over the next few years.

Rapidly increasing demands, a rise in industrialization, consumer awareness, growing sectors, and technical improvements are fueling the expansion of the Chlorella industry. Sales and revenue in this sector have increased at an exponential rate. The market’s size and growth are both expected to increase thanks to the factors driving the market’s expansion over the projected period.

Leading businesses in the worldwide Chlorella market are investing heavily in R&D in order to build a larger client base and expand their share of the market by reintroducing improved products to consumers. All of the companies’ strategies, as well as their financial health, revenue, gross margin, and growth rate, are detailed in the study.

Recent Development

  • In 2022, the Profuture developed light microalgae for plant-based protein without fishiness. Researchers have developed microalgae strains boasting improved taste.

Some of the major players operating in the chlorella market are:

  • GONG BIH ENTERPRISHE CO.,LTD. (Taiwan)
  • E.I.D. – Parry (India) Limited (India)
  • Far East Bio-Tec Co., Ltd. (Taiwan)
  • Yaeyama Shokusan Co., Ltd. (Japan)
  • Fuqing King Dnarmsa Spirulina Co.,Ltd. (China)
  • Tianjin Norland Biotech Co., Ltd (China)
  • STAUBER Ingredients For Innovation (U.S.)
  • Sure Chemical Co., Ltd. (China)
  • Green Source Organics (U.S.)
  • SUN CHLORELLA CORP (U.S.)
  • FEMICO (Taiwan)
  • Taiwan Chlorella Manufacturing Company (Taiwan)
  • Yaeyama Shokusan Co., Ltd. (Japan)
  • Kshipra Biotech Private Limited (India)
  • Kuber Impex Ltd. (India)
  • Divyagro (India)

Download the Complete Research Study Here in PDF Format @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-chlorella-market

Market intelligence platform will help you understand:

  • Identify emerging market trends & dynamics
  • Market intelligence with quality and accuracy
  • Benchmark against competitors & industry
  • Explore competitive strategy & market share
  • Discover regional market opportunities
  • Deliverable formats include PDF, PPT, Excel & Online Dashboard

Data Bridge Market Research employs comprehensive and iterative research methodology focused on minimizing deviance in order to provide the most accurate estimates and forecast possible. The company utilizes a combination of bottom-up and top-down approaches for segmenting and estimating quantitative aspects of the market. In Addition, a recurring theme prevalent across all our research reports is data triangulation that looks market from three different perspectives.

Our market estimates and forecasts are derived through simulation models. A unique model is created customized for each study. Gathered information for market dynamics, technology landscape, application development and pricing trends is fed into the model and analyzed simultaneously. These factors are studied on a comparative basis, and their impact over the forecast period is quantified with the help of correlation, regression and time series analysis. Market forecasting is performed via a combination of economic tools, technological analysis, and industry experience and domain expertise.

Opportunities for Key Players:

  • Health benefits increasing use pof chlorella

The increased use of chlorella due to rising benefits such as improved immunity, lowered blood sugar levels and others in the human beings are important factors for the growth of the market. Moreover, Chlorella is used as an ingredient in the cosmetics added for the pigmentation and are also the rich source of chlorophyll used in the haircare, lotions and other products. All these factors are generating certain lucrative opportunities for the chlorella market.

Additionally, the growing awareness regarding the health benefits associated with the chlorella supplements will further propel the growth of the market.

Drivers

  • Health benefits of chlorella supplements

The primary factor driving the chlorella market is rising health consciousness among people all over the world. The increased use of chlorella due to rising benefits such as improved immunity, reduced gastric ulcers, lowered blood sugar levels and increased haemoglobin content in the human beings are important factors for the growth of the market. Moreover, rise in the cultivation of chlorella due to increased demands has resulted in the growth of the chlorella market.

  • Rise in uptake in the personal care industries

The increased use of chlorella among various end-users and cosmetic industries is the factor driving the market growth. Chlorella is used as an ingredient in the cosmetics added for the pigmentation and are also the rich source of chlorophyll used in the haircare, lotions and other products which is fuelling the growth of the chlorella market.

Key Market Segments Covered in Chlorella Industry Research

Source

  • Chlorella Vulgaris
  • Chlorella Pyrenoidosa
  • Chlorella Ellipsoidea
  • Other Sources

Type

Application

  • Food Industry
  • Pharmaceutical Industry
  • Cosmetic Industry

Technology

  • Closed Pods
  • Autotrophic
  • Heterotrophic

Product

Distribution Channel

  • Distributors
  • Direct-to-Consumer

Browse More About This Research Report @ https://www.databridgemarketresearch.com/reports/global-chlorella-market

Key Drivers:

  • Health benefits of chlorella supplements

The primary factor driving the chlorella market is rising health consciousness among people all over the world. The increased use of chlorella due to rising benefits such as improved immunity, reduced gastric ulcers, lowered blood sugar levels and increased haemoglobin content in the human beings are important factors for the growth of the market. Moreover, rise in the cultivation of chlorella due to increased demands has resulted in the growth of the chlorella market.

  • Rise in uptake in the personal care industries

The increased use of chlorella among various end-users and cosmetic industries is the factor driving the market growth. Chlorella is used as an ingredient in the cosmetics added for pigmentation and are also the rich source of chlorophyll used in the haircare, lotions and other products which is fuelling the growth of the chlorella market.

Chlorella Market Regional Analysis/Insights:

The countries covered in the chlorella market report are U.S., Canada and Mexico in North America, Germany, Sweden, Poland, Denmark, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Asia-Pacific dominates the chlorella market because of rising personal care industries along with the pharmaceutical sector within the region

North America is expected to grow over the forecasted period from 2022 to 2029 due to the growing adoption of the dietary supplements for weight loss within the region

All country-based analysis chlorella market is further analyzed based on maximum granularity into further segmentation. The chlorella market on the basis of source has been segmented into chlorella vulgaris, chlorella pyrenoidosa, chlorella ellipsoidea and other sources. Based on application, the chlorella market is segmented into food industry, pharmaceutical industry, cosmetic industry and others. Others have been further segmented into feed industry and biofuel. The chlorella market is also segmented on the basis of type into organic and inorganic. 

Restraints

The high cost associated with research and development activities and the availability of alternatives will act as major restraints on the growth of the chlorella market in the forecast period. The cost and the complexities related to the development of the products is further anticipated to restraint the growth of the market.

This chlorella market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the chlorella market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Impact and Current Market Scenario of Raw Material Shortage and Shipping Delays

Data Bridge Market Research offers a high-level analysis of the market and delivers information by keeping in account the impact and current market environment of raw material shortage and shipping delays. This translates into assessing strategic possibilities, creating effective action plans, and assisting businesses in making important decisions.

Table of Contents:

  1. Introduction
  2. Market Segmentation
  3. Executive Summary
  4. Premium Insights
  5. Global Chlorella Market: Regulations
  6. Market Overview
  7. Global Chlorella Market, By Source
  8. Global Chlorella Market, By Type
  9. Global Chlorella Market, By Application
  10. Global Chlorella Market, By Technology
  11. Global Chlorella Market, By Product
  12. Global Chlorella Market, By Distribution Channel
  13. Global Chlorella Market, By Region
  14. Global Chlorella Market: Company Landscape
  15. SWOT Analyses
  16. Company Profile
  17. Questionnaires
  18. Related Reports

Get the Complete Table of Contents @ https://www.databridgemarketresearch.com/toc/?dbmr=global-chlorella-market

Explore More Reports:

  • Ashwagandha Market, By Type (KSM-66, Sensoril, Hydro-alcoholic Ashwagandha, Crude Ashwagandha), Product Type (Ashwagandha Root Product, Ashwagandha Leaf Products, Ashwagandha Leaf and Root Mix Product), Withanolides Content (1% Withanolides, 2% Withanolides, 2.5% Withanolides, 5% Withanolides, 10% Withanolides), Category (Regular, Full Spectrum), Form (Powder, Capsule, Liquid), Function (Improved Stamina, Improved Immunity, Overall Wellbeing, Reduced Anxiety and Stress, Brain Health, Muscle Strength), Distribution Channel (B2B, B2C), Application (Food and Beverages, Pharmaceutical, Dietary Supplements, Sports Nutrition, Others) https://www.databridgemarketresearch.com/reports/global-ashwagandha-market
  • Nutritional Food Market, Products (Bakery and Cereals, Dairy Products, Meat, Fish and Eggs, Soy Products, Fats and Oils, and Others), Ingredients (Carotenoids, Dietary Fibres and Carbohydrates, Fatty Acids, Minerals, Anti-oxidants, Prebiotics, and Probiotics, Vitamins, Proteins, and Others), Application (Sports Nutrition, Weight Management, Immunity, Digestive Health, Clinical Nutrition, Cardio Health, Paediatric, Veterinary, Medical, Personalized and Others), Health (Allergies, Bone and Joint, Glucose Management, Cancer, Cardiovascular, Maternal and Infant and Skin) https://www.databridgemarketresearch.com/reports/global-nutritional-food-market
  • Vitamin C Market, By Type (Sodium Ascorbate, Calcium Ascorbate, Potassium Ascorbate, Magnesium Ascorbate, Ascorbic Acid 90% Granulation, D-Isoascorbic Acid, Ascorbic Acid 95% Granulation, Ascorbic Acid 97% Granulation, Coated Vitamin C, Others), Source (Natural, Synthetic), Process (Reichsteiz, Two-stage Fermentation), Form (Tonic, Tablet, Granules, Injection), Application (Pharmaceutical, Cosmetics, Food, and Beverage, Animal Feed) https://www.databridgemarketresearch.com/reports/global-vitamin-c-market
  • Jam, Jelly and Preserves Market, By Product Type (Jam and Jelly, Marmalade, Preserve), Flavours (Mango, Blackberry, Grapes, Raspberry, Others), Ingredient Type (Pectin, Fruit and Fruit Juice, Sweeteners, Essence, Others), Packaging Type (Glass Bottle, Jar, Polypropylene, Others). Distribution Channel (Supermarket/Hypermarket, Convenience Store, Online Store, Other), Country (U.S., Canada, Mexico, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, U.A.E, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-jam-jelly-and-preserves-market
  • Animal Feed Market, By Type (Acidifiers, Probiotics, Enzyme, Antioxidants, Antibiotics, Amino Acids, Vitamins, Minerals, Others), Species (Poultry, Ruminants, Aqua, Swine, Others), Form (Pellets, Crumbles, Mash, Others), Country (U.S., Canada, Mexico, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, UAE, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-animal-feed-market
  • Low-Carb Diet Market, By Type of Diet (A Typical Low-Carb Diet, Ketogenic Diet, Low-Carb High-Fat (LCHF), Low-Carb Paleo Diet, The Atkins Diet, Eco-Atkins, Zero-Carb, Low-Carb Mediterranean Diet), Source (Grains, Fruits, Vegetables, Milk, Nuts, Seeds, Legumes), Application (Weight Loss, Metabolic Syndrome, Diabetes, High Blood Pressure, Cardiovascular Disease), Distribution Channel (Hypermarket and Supermarket, Specialty Stores, Convenience Stores, Online) https://www.databridgemarketresearch.com/reports/global-low-carb-diet-market
  • Nutritional Beverages Market, By Parameter (Vitamin Profile, Mineral Profile, Fat Profile, Moisture, Proteins, Total Dietary Fibre, Sugar Profile, Cholesterol, Calories), Product Type (Beverages, Snacks, Bakery and Confectionery, Meat and Poultry, Sauces, Dressings, Condiments, Dairy and Desserts, Fruits and Vegetables, Edible Fats and Oils, Baby Food, Others), Application (Health and Fitness, Medical, Sports, Others), Objective (Product Labelling, New Product Development, Regulation Compliance) https://www.databridgemarketresearch.com/reports/global-nutritional-beverages-market
  • White Chocolate Market, By Product (White Chocolate Truffles, White Chocolate Bars, White Chocolate Bulk), Colour (White, Pale Yellow, Ivory), Snack Foods (Chips, Cookies, Popcorns, and Cupcakes), Beverages (Milkshakes, Coffee, and Smoothies), Cosmetics (Wax, Nail Enamel, Oil), Distributional Channel (Super Markets, Convenience Stores, Non-Grocery Retailers, Others), End User (Confectionery, Food and Beverage, Cosmetics, Pharmaceuticals) https://www.databridgemarketresearch.com/reports/global-white-chocolate-market
  • Popcorn Market, By Product (Ready-to-Eat and Microwave), Flavour (Sweet and Savoury), Shape (Mushroom and Butterfly), Application (Home and Commercial) Distribution Channel (Store-Based and Non-Store Based), Country (U.S., Canada, Mexico, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, UAE, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-popcorn-market
  • Fertility Supplements Market, By  Ingredient (Natural, Synthetic and Blend of Natural and Synthetic), Type (Capsules, Soft Gels, Powders, Liquids and Others), Procedure (IVF with ICSI, IUI, Surrogacy, IVF without ICSI and Others), Service (Frozen Non-Donor, Egg and Embryo Banking, Fresh Non-Donor, Fresh Donor and Frozen Donor), Application (Men and Women), End User (Fertility Clinics, Hospitals, Surgical Centres, Clinical Research Institutes and Others), Distribution Channel (Over The Counter (OTC)  and Prescribed), Country (U.S., Canada, Mexico, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, UAE, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-fertility-supplements-market

About Data Bridge Market Research:

An absolute way to forecast what the future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:

Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- [email protected]

Cannabis

Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0

Published

on

Continue Reading

Cannabis

IM Cannabis Reports First Quarter Financial Results

Published

on

im-cannabis-reports-first-quarter-financial-results

IMC prepares for accelerated growth after legalization in Germany and recovers from the impact of the Israel-Hamas war.

TORONTO and GLIL YAM, Israel, May 8, 2024 /PRNewswire/ — IM Cannabis Corp. (the “Company” or “IMC“) (NASDAQ: IMCC) (CSE: IMCC), an international medical cannabis company, announced its financial results today for the first quarter ended March 31, 2024. All amounts are reported in Canadian dollars and compared to the quarter ended March 31, 2023, unless otherwise stated.

Q1 2024 Financial Highlights

  • 13% Revenue increase vs. Q4 2023 of $12.1M vs. $10.7M and 4% decrease vs. Q1 2023 of $12.5M

 

  • 125% Gross profit increase vs. Q4 2023 of $1.8M vs. $0.8 and 39% Gross profit decrease vs. Q1 2023 of $2.9M

 

  • 29% decrease in operating expenses vs. Q1 2023 excluding the one-time Oranim revoke related losses of $4.6M vs. $6.5M and 14% increase including Oranim

 

  • 12% increase of Non-IFRS Adjusted EBITDA loss to $2.1M

Operational Highlights

The Company intends to complete a non-brokered private placement (the “Offering“) of secured convertible debentures of the Company (each, a “Debenture“) for aggregate proceeds of up to C$2,500,000. The Debentures will mature on the date that is 12 months from the date of issuance and will not incur interest except in the event of default. The Debentures are being issued to holders of short term loans and obligations owed by the Company or its wholly owned subsidiaries. The principal of the Debenture may be converted into common shares in the Company (each, a “Share“) at a conversion price of $1.08 per Share.

Management Commentary 

“With the April 1st cannabis legalization in Germany, we are augmenting our focus and resources on the German market, where we expect to see the biggest growth potential, and the best return on investment. While it is still too early to make any predictions, our sales in Germany almost doubled during the month of April,” said Oren Shuster, Chief Executive Officer of IMC. “Looking back on the first month post legalization in Germany, I see that we have the infrastructure and the supply agreements in place to continue delivering the accelerated growth we have already seen in April. We will also ensure that we have the necessary resources in place for success.”   

“In 2023 we completely restructured, becoming a very lean and agile company, leaning into active cost management. This process is reflected in the numbers, our G&A decreased 27% vs Q1 2023” said Uri Birenberg, Chief Financial Officer of IMC. “While our results have recovered from the impact of the Israel-Hamas war, our revenue was still effected by both an unfavorable exchange rate, as well as price reductions to sell off inventory.”

Q1 2024 Conference Call 

The Company will host a Zoom web conference call today at 9:00 a.m. ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration.

If you are unable to join us live, a recording of the call will be available on our website at https://investors.imcannabis.com/ within 24 hours after the call.

Q1 2024 Financial Results

  • Revenues for the first quarter of 2024 were $12.1 million compared to $12.5 million in the first quarter of 2023, a decrease of 3%. The decrease is mainly due an exchange rate effect of about $0.2 million and decrease in avg. price per sale due to increased competition.

 

  • Gross profit for the first quarter of 2024 was $1.8 million, compared to $2.9 million in Q1 2024, a decrease of 39%. The downside is attributed mainly to the slow-moving stock that was moved out at a lower price and an exchange rate difference totaling $0.4 million and $0.64 million cost of sales loss due to an inventory erase of the slow-moving stock. Company fair value adjustment was $0 and $0.4 million for the Q1 2024 and Q1 2023 respectively.

 

  • Total Dried Flower sold in Q1 2024 was approximately 1,873 kg with an average selling price of $5.68 per gram, compared to approximately 1,842kg in Q1 2023, with an average selling price of $6.59 per gram. This difference is mainly due to increased competition within the retail segment, and mid-range stock discounts to move out slow moving stock.

 

  • Total operating expenses in Q1 2024 were $7.4 million compared to $6.5 million in Q1 2023. The increase is due to the other operating expenses related to Oranim Deal revoke, with an expected losses of $2.8 million. Adjusting for this one-time losses, Q1 2024 operating expenses were $4.6 million compared to $6.5 million in Q1 2023, a decrease of 29%.

 

  • G&A Expenses in Q1 2024 were $2.3 million, compared to $3.2 million in Q1 2023, a decrease of 28%. The decrease in the G&A expense is attributable mainly to salaries and professional services of $0.64 million.

 

  • Selling and Marketing Expenses in Q1 2024 were $2.3 million, compared to $2.8 million in Q1 2023, a decrease of 18% mainly due to a decrease in Salaries and professional services of $0.5 million.

 

  • Net Loss from continuing operations in Q1 2024 was $6.0 million, compared to $0.9 million in Q12023.

 

  • Basic and diluted Loss per Share in Q1 2024 was $0.42, compared to a loss of $0.05 per Share in Q1 2023.

 

  • Non-IFRS Adjusted EBITDA loss in Q1 2024 was $2.1 million, compared to an Adjusted EBITDA loss of $1.9 million in Q1 2023 an increase of 10%.

 

  • Cash and Cash Equivalents as of March 31, 2024, were $1.0 million compared to $1.8 million in December 31, 2023.

 

  • Total assets as of March 31, 2024, were $41.1 million, compared to $48.8 million in December 31, 2023, a decrease of 16%. The decrease is mainly attributed to the goodwill reduction due to Oranim agreement cancelation of about $2.8M, a reduction in Inventory of $2.1 million, reduction of Cash and cash equivalents of $0.8M and reduction in Trade payables of $1.2 million.

 

  • Total Liabilities as of March 31, 2024, were $32.8 million, compared to $35.1 in December 31, 2023, a decrease of about 7%. The decrease was mainly due to the reduction in other accounts payables and accrued expenses of $1.8 million and reduction in the PUT option liability of $0.7 million.

 

The Company’s financial statements as of March 31, 2024 includes a note regarding the Company’s ability to continue as a going concern. The Company’s Q1 2024 financial results do not include any adjustments relating to the recoverability and classification of assets or liabilities that might be necessary should the Company be unable to continue as a going concern. For more information, please refer to the “Liquidity and Capital Resources” and “Risk Factors” sections in the Company’s management’s discussion and analysis for the quarter ended March 31, 2024.

Non-IFRS Measures

This press release makes reference to “Gross Margin” and “Adjusted EBITDA”, which are financial measures that are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. These measures are provided as complementary information to the Company’s IFRS measures by providing further understanding of our results of operations from management’s perspective. Accordingly, these measures should neither be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS.

For an explanation of how management defines Gross Margin and Adjusted EBITDA, see the Company’s management’s discussion and analysis for the period ended March 31, 2024, available under the Company’s SEDAR+ profile at www.sedarplus.ca on EDGAR at www.sec.gov/edgar.
We reconcile these non-IFRS financial measures to the most comparable IFRS measures as set out below.

 

 

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

Canadian Dollars in thousands

March 31,
2024

December 31,
2023

Note

(Unaudited)

ASSETS

CURRENT ASSETS:

Cash and cash equivalents

$           1,048

$           1,813

Trade receivables

6,506

7,651

Advances to suppliers

780

936

Other accounts receivable

3,732

3,889

Inventories

3

7,901

9,976

19,967

24,265

NON-CURRENT ASSETS:

Property, plant and equipment, net

4,939

5,058

Investments in affiliates

2,078

2,285

Right-of-use assets, net

1,243

1,307

Intangible assets, net

5,440

5,803

Goodwill

7,442

10,095

21,142

24,548

Total assets

$          41,109

$          48,813

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

 

 

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

Canadian Dollars in thousands

March 31,
2024

December 31,
2023

Note

(Unaudited)

LIABILITIES AND EQUITY

CURRENT LIABILITIES:

 

Trade payables

$      9,511

$      9,223

Bank loans and credit facilities

11,941

12,119

Other accounts payable and accrued expenses

4,440

6,218

Accrued purchase consideration liabilities

2,165

2,097

PUT Option liability

1,967

2,697

Current maturities of operating lease liabilities

461

454

30,485

32,808

NON-CURRENT LIABILITIES:

 

Warrants measured at fair value

4

137

38

Operating lease liabilities

744

815

Long-term loans

401

394

Employee benefit liabilities, net

96

95

Deferred tax liability, net

902

963

2,280

2,305

Total liabilities

32,765

35,113

EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:

5

Share capital and premium

253,887

253,882

Translation reserve

1,399

95

Reserve from share-based payment transactions

9,664

9,637

Accumulated deficit

(255,431)

(249,145)

Total equity attributable to equity holders of the Company

9,519

14,469

 Non-controlling interests

(1,175)

(769)

Total equity

8,344

13,700

Total liabilities and equity

$  41,109

$     48,813

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

 

 

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS

AND OTHER COMPREHENSIVE INCOME (UNAUDITED)

Canadian Dollars in thousands, except per share data

Three months ended

March 31,

Note

2024

2023 (*)

Revenues

$      12,063

$      12,529

Cost of revenues

10,274

9,286

Gross profit before fair value adjustments

1,789

3,243

Fair value adjustments:

Realized fair value adjustments on inventory sold in the period

(10)

(339)

Total fair value adjustments

(10)

(339)

Gross profit

1,779

2,904

General and administrative expenses

2,332

3,175

Selling and marketing expenses

2,292

2,805

Restructuring expenses

283

Share-based compensation

32

258

Other operating expenses

9

2,753

Total operating expenses

7,409

6,521

Operating loss

5,630

3,617

Finance income

4

(14)

3,530

Finance expense

(487)

(795)

Finance income, net

(501)

2,735

Gain (loss) before income taxes

(6,131)

(882)

Income tax benefit

(111)

(16)

Net )loss( gain

(6,020)

(866)

Other comprehensive income that will not be reclassified to profit or loss in
 subsequent periods:

Total other comprehensive income that will not be reclassified to profit or loss
 in subsequent periods

67

36

Exchange differences on translation to presentation currency

1,330

(562)

Total other comprehensive income (loss) that will not be reclassified to profit
 or loss in subsequent periods

1,397

(526)

Other comprehensive income that will be reclassified to profit or loss in
 subsequent periods:

Adjustments arising from translating financial statements of foreign operation

(35)

155

Total other comprehensive income (loss) that will be reclassified to profit or loss
 in subsequent periods

(35)

155

Total other comprehensive income (loss)

1,362

(371)

Total comprehensive loss

$       (4,658)

$       (1,237)

 

 

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS

AND OTHER COMPREHENSIVE INCOME (UNAUDITED)

Canadian Dollars in thousands, except per share data

Three months ended

March 31,

Note

2024

2023 (*)

Net income (loss) attributable to:

Equity holders of the Company

(5,623)

(600)

Non-controlling interests

(397)

(266)

$       (6,020)

$           (866)

Total comprehensive income (loss) attributable to:

Equity holders of the Company 

(4,252)

(959)

Non-controlling interests 

(406)

(278)

$       (4,658)

$       (1,237)

Net income (loss) per share attributable to equity holders of the Company

7

Basic and diluted (loss) gain per share (in CAD)

$           (0.42)

$           (0.05)

Earnings (loss) per share attributable to equity holders of the Company
 from continuing operations:

Basic and diluted (loss) gain per share (in CAD)

$         (0.42)

$          (0.05)

(*) See note 1 regarding figures disclosure.

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

 

 

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

Canadian Dollars in thousands

Three months ended

March 31,

2024

2023 (*)

Cash provided by operating activities:

Net income (loss) for the period

$    (6,020)

$          43

Adjustments for non-cash items:

Fair value adjustment on sale of inventory

10

339

Fair value adjustment on Warrants, investments and accounts receivable

100

(3,636)

Depreciation of property, plant and equipment

147

174

Amortization of intangible assets

452

456

Depreciation of right-of-use assets

118

179

Impairment of goodwill

2,753

Finance expenses, net

401

635

Deferred tax liability, net

(69)

(150)

Share-based payment

32

258

Restructuring expense

283

3,944

(1,462)

Changes in working capital:

Decrease (increase) in trade receivables

1,332

1,937

Decrease (increase) in other accounts receivable and advances to suppliers

159

(940)

Decrease (increase) in inventories, net of fair value adjustments

2,159

90

Decrease (increase) in trade payables

663

(6,021)

Changes in employee benefit liabilities, net

(22)

Increase in other accounts payable and accrued expenses

(2,745)

(14)

1,568

(4,970)

Taxes (paid) received

(121)

328

Net cash used in operating activities

(629)

(6,061)

Cash flows from investing activities:

Purchase of property, plant and equipment

(2)

(411)

Payment of purchase consideration

(56)

Net cash used in investing activities

$            (2)

$        (467)

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

 

 

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

Canadian Dollars in thousands

Three months ended

March 31,

2024

2023

Cash flow from financing activities:

   Proceeds from issuance of share capital, net of issuance costs

176

825

   Proceeds from issuance of warrants

(176)

7,027

   Repayment of lease liability

(118)

(175)

   Interest paid – lease liability

(15)

(18)

   Receipt (repayment) of bank loan and credit facilities

(2,856)

(1,046)

   Cash paid for interest

(444)

(56)

   Proceeds from discounted checks

2,581

Net cash (used in) provided by financing activities

(852)

6,557

Effect of foreign exchange on cash and cash equivalents

718

(1,059)

Decrease in cash and cash equivalents

(765)

(1,030)

Cash and cash equivalents at beginning of the period

1,813

2,449

Cash and cash equivalents at end of the period

$      1,048

$     1,419

Supplemental disclosure of non-cash activities:

Right-of-use asset recognized with corresponding lease liability

$           40

$          49

Issuance of shares in payment of debt settlement to a non-independent director of the company

$              –

$        222

(*) See note 1 regarding Figures disclosure.

The accompanying notes are an integral part of the interim condensed consolidated financial statements.

 

About IM Cannabis Corp.

IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has exited operations in Canada to pivot its focus and resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

The IMC ecosystem operates in Israel through Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The Company also  operated in Canada through Trichome Financial Corp and its wholly owned subsidiaries. The Company has exited operations in Canada and considers these operations as discontinued.

Disclaimer for Forward-Looking Statements

This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, “forward-looking statements“). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to: the impact of the Israel-Hamas war on the Company, including its operations and the medical cannabis industry in Israel; the timing and impact of the legalization of medicinal cannabis in Germany, including, the Company having it “all in house”; the Company being positioned to take advantage of the legalization; the Company’s growth in 2024; the market growth for medicinal cannabis in Germany;  the stated benefits of the Company’s EU-GMP processing facility and an EU-GDP logistics center; the Company to host a teleconference meeting as stated; and the Company’s stated goals, scope, and nature of operations in Germany, Israel, and other jurisdictions the Company may operate.

Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the Company’s ability to focus and resources to achieve sustainable and profitable growth in its highest value markets; the Company’s ability to mitigate the impact of the Israel-Hamas war on the Company; the Company’s ability to take advantage of the legalization of medicinal cannabis in Germany; the Company’s ability to host a teleconference meeting as stated; and the Company’s ability to carry out its stated goals, scope, and nature of operations in Germany, Israel, and other jurisdictions the Company may operate.

The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the “Group“) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the inability of the Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the company to grow and/or maintain sales; the inability of the Company to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; the Company’s inability to take advantage of the legalization of medicinal cannabis in Germany; and the Company’s inability to host a teleconference meeting as stated.

Please see the other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual report dated March 28, 2024, which is available on the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

Company Contact: 

Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]

Oren Shuster, CEO
IM Cannabis Corp.
+972-77-3603504

Logo – https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/im-cannabis-reports-first-quarter-financial-results-302139688.html

Continue Reading

Cannabis

Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III

Published

on

Continue Reading
Advertisement

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania